Persistence of immune response following bivalent HPV vaccination:A follow-up study among girls routinely vaccinated with a two-dose schedule
| Autor: | Rutger M. Schepp, Tessa M Schurink-van 't Klooster, Robine Donken, Fiona R. M. van der Klis, Hester E. de Melker |
|---|---|
| Přispěvatelé: | Epidemiology and Data Science |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty HPV Adolescent 030106 microbiology Antibody Affinity Two-dose schedule Antibodies Viral Avidity Bivalent (genetics) Cohort Studies GMC 03 medical and health sciences Antibody concentration 0302 clinical medicine Immune system Internal medicine Surveys and Questionnaires Medicine Humans 030212 general & internal medicine Papillomavirus Vaccines Child Immunization Schedule Human papillomavirus 16 General Veterinary General Immunology and Microbiology biology medicine.diagnostic_test Human papillomavirus 18 business.industry Immunization Programs Papillomavirus Infections Public Health Environmental and Occupational Health Follow up studies Antibodies Neutralizing Vaccination Infectious Diseases Immunoassay Antibody Formation biology.protein Molecular Medicine Female Antibody business Vaccine Cohort study Follow-Up Studies |
| Zdroj: | Schurink-van 't Klooster, T M, Donken, R, Schepp, R M, van der Klis, F R M & de Melker, H E 2018, ' Persistence of immune response following bivalent HPV vaccination : A follow-up study among girls routinely vaccinated with a two-dose schedule ', Vaccine, vol. 36, no. 49, pp. 7580-7587 . https://doi.org/10.1016/j.vaccine.2018.10.018 Vaccine, 36(49), 7580-7587. Elsevier BV |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2018.10.018 |
| Popis: | Background: In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. Methods: A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay. Results: Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76–78% and 81–82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16–29% at month 7, 20–32% at month 12 and 19–32% at month 24. Conclusions: GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect